Delafloxacin, an alternative treatment for levofloxacin-resistant staphylococci in osteoarticular infections: To use or not to use?

Diagn Microbiol Infect Dis. 2024 Dec;110(4):116518. doi: 10.1016/j.diagmicrobio.2024.116518. Epub 2024 Sep 2.

Abstract

Susceptibility of delafloxacin on 199 osteoarticular levofloxacin-resistant staphylococci strains was reported in 49% and 1% using SSTI S. aureus breakpoint (0.25 mg/L) and general S. aureus breakpoint (0.016 mg/L) respectively. Fifty percents levofloxacin-resistant staphylococci showed resistance to delafloxacin using CA-SFM/EUCAST recommendations. Microbiological societies should define new breakpoints especially for CoNS.

Keywords: Delafloxacin; Fluoroquinolones; Osteoarticular infections; Staphylococcus.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Drug Resistance, Bacterial*
  • Fluoroquinolones* / pharmacology
  • Fluoroquinolones* / therapeutic use
  • Humans
  • Levofloxacin* / pharmacology
  • Levofloxacin* / therapeutic use
  • Microbial Sensitivity Tests*
  • Staphylococcal Infections* / drug therapy
  • Staphylococcal Infections* / microbiology
  • Staphylococcus* / drug effects

Substances

  • Anti-Bacterial Agents
  • Levofloxacin
  • Fluoroquinolones
  • delafloxacin